Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Tsang Website

Kwong Yok Tsang, Ph.D.

Selected Publications
1)  Yokokawa J, Cereda V, Remondo C, Gulley JL, Arlen PM, Schlom J, Tsang KY.
Enhanced functionality of CD4+CD25(high)FoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer.
Clin. Cancer Res. 14: 1032-40, 2008. [Journal]
2)  Gulley JL, Arlen PM, Tsang KY, Yokokawa J, Palena C, Poole DJ, Remondo C, Cereda V, Jones JL, Pazdur MP, Higgins JP, Hodge JW, Steinberg SM, Kotz H, Dahut WL, Schlom J.
Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma.
Clin. Cancer Res. 14: 3060-9, 2008. [Journal]
3)  Lechleider RJ, Arlen PM, Tsang KY, Steinberg SM, Yokokawa J, Cereda V, Camphausen K, Schlom J, Dahut WL, Gulley JL.
Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant.
Clin. Cancer Res. 14: 5284-91, 2008. [Journal]
4)  Arlen PM, Skarupa L, Pazdur M, Seetharam M, Tsang KY, Grosenbach DW, Feldman J, Poole DJ, Litzinger M, Steinberg SM, Jones E, Chen C, Marte J, Parnes H, Wright J, Dahut W, Schlom J, Gulley JL.
Clinical safety of a viral vector based prostate cancer vaccine strategy.
J. Urol. 178: 1515-20, 2007. [Journal]
5)  Yokokawa J, Bera TK, Palena C, Cereda V, Remondo C, Gulley JL, Arlen PM, Pastan I, Schlom J, Tsang KY.
Identification of cytotoxic T-lymphocyte epitope(s) and its agonist epitope(s) of a novel target for vaccine therapy (PAGE4).
Int. J. Cancer. 121: 595-605, 2007. [Journal]
6)  Palena C, Polev DE, Tsang KY, Fernando RI, Litzinger M, Krukovskaya LL, Baranova AV, Kozlov AP, Schlom J.
The human T-box mesodermal transcription factor Brachyury is a candidate target for T-cell-mediated cancer immunotherapy.
Clin. Cancer Res. 13: 2471-8, 2007. [Journal]
7)  Arlen PM, Gulley JL, Parker C, Skarupa L, Pazdur M, Panicali D, Beetham P, Tsang KY, Grosenbach DW, Feldman J, Steinberg SM, Jones E, Chen C, Marte J, Schlom J, Dahut W.
A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer.
Clin. Cancer Res. 12: 1260-9, 2006. [Journal]
8)  Gelbard A, Garnett CT, Abrams SI, Patel V, Gutkind JS, Palena C, Tsang KY, Schlom J, Hodge JW.
Combination chemotherapy and radiation of human squamous cell carcinoma of the head and neck augments CTL-mediated lysis.
Clin. Cancer Res. 12: 1897-905, 2006. [Journal]
9)  Hodge JW, Greiner JW, Tsang KY, Sabzevari H, Kudo-Saito C, Grosenbach DW, Gulley JL, Arlen PM, Marshall JL, Panicali D, Schlom J.
Costimulatory molecules as adjuvants for immunotherapy.
Front. Biosci. 11: 788-803, 2006. [Journal]
10)  Garnett CT, Greiner JW, Tsang KY, Kudo-Saito C, Grosenbach DW, Chakraborty M, Gulley JL, Arlen PM, Schlom J, Hodge JW.
TRICOM vector based cancer vaccines.
Curr. Pharm. Des. 12: 351-61, 2006. [Journal]
11)  Hassan R, Williams-Gould J, Steinberg SM, Liewehr DJ, Yokokawa J, Tsang KY, Surawski RJ, Scott T, Camphausen K.
Tumor-directed radiation and the immunotoxin SS1P in the treatment of mesothelin-expressing tumor xenografts.
Clin. Cancer Res. 12: 4983-8, 2006. [Journal]
12)  Tsang KY, Palena C, Yokokawa J, Arlen PM, Gulley JL, Mazzara GP, Gritz L, Yafal AG, Ogueta S, Greenhalgh P, Manson K, Panicali D, Schlom J.
Analyses of recombinant vaccinia and fowlpox vaccine vectors expressing transgenes for two human tumor antigens and three human costimulatory molecules.
Clin. Cancer Res. 11: 1597-607, 2005. [Journal]
13)  Arlen PM, Gulley JL, Todd N, Lieberman R, Steinberg SM, Morin S, Bastian A, Marte J, Tsang KY, Beetham P, Grosenbach DW, Schlom J, Dahut W.
Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer.
J. Urol. 174: 539-46, 2005. [Journal]
14)  Correale P, Cusi MG, Tsang KY, Del Vecchio MT, Marsili S, Placa ML, Intrivici C, Aquino A, Micheli L, Nencini C, Ferrari F, Giorgi G, Bonmassar E, Francini G.
Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients.
J. Clin. Oncol. 23: 8950-8, 2005. [Journal]
15)  Gulley JL, Arlen PM, Bastian A, Morin S, Marte J, Beetham P, Tsang KY, Yokokawa J, Hodge JW, Ménard C, Camphausen K, Coleman CN, Sullivan F, Steinberg SM, Schlom J, Dahut W.
Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer.
Clin. Cancer Res. 11: 3353-62, 2005. [Journal]
16)  Correale P, Cusi MG, Del Vecchio MT, Aquino A, Prete SP, Prete S, Tsang KY, Micheli L, Nencini C, La Placa M, Montagnani F, Terrosi C, Caraglia M, Formica V, Giorgi G, Bonmassar E, Francini G.
Dendritic cell-mediated cross-presentation of antigens derived from colon carcinoma cells exposed to a highly cytotoxic multidrug regimen with gemcitabine, oxaliplatin, 5-fluorouracil, and leucovorin, elicits a powerful human antigen-specific CTL response with antitumor activity in vitro.
J. Immunol. 175: 820-8, 2005. [Journal]
17)  Yokokawa J, Palena C, Arlen P, Hassan R, Ho M, Pastan I, Schlom J, Tsang KY.
Identification of novel human CTL epitopes and their agonist epitopes of mesothelin.
Clin. Cancer Res. 11: 6342-51, 2005. [Journal]
18)  Yang S, Tsang KY, Schlom J.
Induction of higher-avidity human CTLs by vector-mediated enhanced costimulation of antigen-presenting cells.
Clin. Cancer Res. 11: 5603-15, 2005. [Journal]
19)  Marshall JL, Gulley JL, Arlen PM, Beetham PK, Tsang KY, Slack R, Hodge JW, Doren S, Grosenbach DW, Hwang J, Fox E, Odogwu L, Park S, Panicali D, Schlom J.
Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas.
J. Clin. Oncol. 23: 720-31, 2005. [Journal]
20)  Palena C, Foon KA, Panicali D, Yafal AG, Chinsangaram J, Hodge JW, Schlom J, Tsang KY.
Potential approach to immunotherapy of chronic lymphocytic leukemia (CLL): enhanced immunogenicity of CLL cells via infection with vectors encoding for multiple costimulatory molecules.
Blood. 106: 3515-23, 2005. [Journal]
21)  Tsang KY, Palena C, Gulley J, Arlen P, Schlom J.
A human cytotoxic T-lymphocyte epitope and its agonist epitope from the nonvariable number of tandem repeat sequence of MUC-1.
Clin. Cancer Res. 10: 2139-49, 2004. [Journal]
22)  Schlom J, Palena C, Greiner JW, Tsang KY, Grosenbach DW, Sabzevari H, Gulley JL, Arlen PM, Kass E, Hodge JW.
Combinatorial vaccine strategies and the use of molecular arrays to characterize T-cell activation.
Developments in biologicals. 116: 27-47, 2004. [Journal]
23)  Palena C, Zhu M, Schlom J, Tsang KY.
Human B cells that hyperexpress a triad of costimulatory molecules via avipox-vector infection: an alternative source of efficient antigen-presenting cells.
Blood. 104: 192-9, 2004. [Journal]
24)  Garnett CT, Palena C, Chakraborty M, Chakarborty M, Tsang KY, Schlom J, Hodge JW.
Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes.
Cancer Res. 64: 7985-94, 2004. [Journal]
25)  Arlen PM, Gulley JL, Palena C, Marshall J, Schlom J, Tsang KY.
A novel ELISPOT assay to enhance detection of antigen-specific T cells employing antigen-presenting cells expressing vector-driven human B7-1.
J. Immunol. Methods. 279: 183-92, 2003. [Journal]
26)  Palena C, Schlom J, Tsang KY.
Differential gene expression profiles in a human T-cell line stimulated with a tumor-associated self-peptide versus an enhancer agonist peptide.
Clin. Cancer Res. 9: 1616-27, 2003. [Journal]
27)  Palena C, Arlen P, Zeytin H, Greiner JW, Schlom J, Tsang KY.
Enhanced expression of lymphotactin by CD8+ T cells is selectively induced by enhancer agonist peptides of tumor-associated antigens.
Cytokine. 24: 128-42, 2003. [Journal]
28)  Hodge JW, Tsang KY, Poole DJ, Schlom J.
General keynote: vaccine strategies for the therapy of ovarian cancer.
Gynecol. Oncol. 88: S97-104; discussion S110-3, 2003. [Journal]
29)  Arlen PM, Gulley JL, Tsang KY, Schlom J.
Strategies for the development of PSA-based vaccines for the treatment of advanced prostate cancer.
Expert review of vaccines. 2: 483-93, 2003. [Journal]
30)  Kass ES, Greiner JW, Kantor JA, Tsang KY, Guadagni F, Chen Z, Clark B, De Pascalis R, Schlom J, Van Waes C.
Carcinoembryonic antigen as a target for specific antitumor immunotherapy of head and neck cancer.
Cancer Res. 62: 5049-57, 2002. [Journal]
31)  Terasawa H, Tsang KY, Gulley J, Arlen P, Schlom J.
Identification and characterization of a human agonist cytotoxic T-lymphocyte epitope of human prostate-specific antigen.
Clin. Cancer Res. 8: 41-53, 2002. [Journal]
32)  Zhu M, Terasawa H, Gulley J, Panicali D, Arlen P, Schlom J, Tsang KY.
Enhanced activation of human T cells via avipox vector-mediated hyperexpression of a triad of costimulatory molecules in human dendritic cells.
Cancer Res. 61: 3725-34, 2001. [Journal]
33)  Wallace PK, Tsang KY, Goldstein J, Correale P, Jarry TM, Schlom J, Guyre PM, Ernstoff MS, Fanger MW.
Exogenous antigen targeted to FcgammaRI on myeloid cells is presented in association with MHC class I.
J. Immunol. Methods. 248: 183-94, 2001. [Journal]
34)  Correale P, Campoccia G, Tsang KY, Micheli L, Cusi MG, Sabatino M, Bruni G, Sestini S, Petrioli R, Pozzessere D, Marsili S, Fanetti G, Giorgi G, Francini G.
Recruitment of dendritic cells and enhanced antigen-specific immune reactivity in cancer patients treated with hr-GM-CSF (Molgramostim) and hr-IL-2. results from a phase Ib clinical trial.
Eur. J. Cancer. 37: 892-902, 2001. [Journal]
35)  Tsang KY, Zhu M, Even J, Gulley J, Arlen P, Schlom J.
The infection of human dendritic cells with recombinant avipox vectors expressing a costimulatory molecule transgene (CD80) to enhance the activation of antigen-specific cytolytic T cells.
Cancer Res. 61: 7568-76, 2001. [Journal]
36)  von Mehren M, Arlen P, Gulley J, Rogatko A, Cooper HS, Meropol NJ, Alpaugh RK, Davey M, McLaughlin S, Beard MT, Tsang KY, Schlom J, Weiner LM.
The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma.
Clin. Cancer Res. 7: 1181-91, 2001. [Journal]
37)  Eder JP, Kantoff PW, Roper K, Xu GX, Bubley GJ, Boyden J, Gritz L, Mazzara G, Oh WK, Arlen P, Tsang KY, Panicali D, Schlom J, Kufe DW.
A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer.
Clin. Cancer Res. 6: 1632-8, 2000. [Journal]
38)  Salazar E, Zaremba S, Arlen PM, Tsang KY, Schlom J.
Agonist peptide from a cytotoxic t-lymphocyte epitope of human carcinoembryonic antigen stimulates production of tc1-type cytokines and increases tyrosine phosphorylation more efficiently than cognate peptide.
Int. J. Cancer. 85: 829-38, 2000. [Journal]
39)  Marshall JL, Hoyer RJ, Toomey MA, Faraguna K, Chang P, Richmond E, Pedicano JE, Gehan E, Peck RA, Arlen P, Tsang KY, Schlom J.
Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses.
J. Clin. Oncol. 18: 3964-73, 2000. [Journal]
40)  Cole DJ, Baron PL, O'Brien P, Reed CE, Schlom J, Tsang KY.
Phase I study of recombinant carcinoembryonic antigen (CEA) vaccinia virus vaccine with post vaccination carcinoembryonic antigen peptide (CAP-1) boost.
Clinical lung cancer. 1: 227-9, 2000. [Journal]
41)  von Mehren M, Arlen P, Tsang KY, Rogatko A, Meropol N, Cooper HS, Davey M, McLaughlin S, Schlom J, Weiner LM.
Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas.
Clin. Cancer Res. 6: 2219-28, 2000. [Journal]
42)  Zhu MZ, Marshall J, Cole D, Schlom J, Tsang KY.
Specific cytolytic T-cell responses to human CEA from patients immunized with recombinant avipox-CEA vaccine.
Clin. Cancer Res. 6: 24-33, 2000. [Journal]
43)  Arlen P, Tsang KY, Marshall JL, Chen A, Steinberg SM, Poole D, Hand PH, Schlom J, Hamilton JM.
The use of a rapid ELISPOT assay to analyze peptide-specific immune responses in carcinoma patients to peptide vs. recombinant poxvirus vaccines.
Cancer Immunol. Immunother. 49: 517-29, 2000. [Journal]
44)  Marshall JL, Hawkins MJ, Tsang KY, Richmond E, Pedicano JE, Zhu MZ, Schlom J.
Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen.
J. Clin. Oncol. 17: 332-7, 1999. [Journal]
45)  Schlom J, Tsang KY, Kantor JA, Abrams SI, Zaremba S, Greiner J, Hodge JW.
Strategies in the development of recombinant vaccines for colon cancer.
Semin. Oncol. 26: 672-82, 1999. [Journal]
46)  Schlom J, Tsang KY, Kantor JA, Abrams SI, Zaremba S, Greiner J, Hodge JW.
Cancer vaccine development.
Expert opinion on investigational drugs. 7: 1439-52, 1998. [Journal]
47)  Correale P, Walmsley K, Zaremba S, Zhu M, Schlom J, Tsang KY.
Generation of human cytolytic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide.
J. Immunol. 161: 3186-94, 1998. [Journal]
48)  Zaremba S, Barzaga E, Zhu M, Soares N, Tsang KY, Schlom J.
Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen.
Cancer Res. 57: 4570-7, 1997. [Journal]
49)  Correale P, Walmsley K, Nieroda C, Zaremba S, Zhu M, Schlom J, Tsang KY.
In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen.
J. Natl. Cancer Inst. 89: 293-300, 1997. [Journal]
50)  Tsang KY, Zhu M, Nieroda CA, Correale P, Zaremba S, Hamilton JM, Cole D, Lam C, Schlom J.
Phenotypic stability of a cytotoxic T-cell line directed against an immunodominant epitope of human carcinoembryonic antigen.
Clin. Cancer Res. 3: 2439-49, 1997. [Journal]
51)  Abrams SI, Hand PH, Tsang KY, Schlom J.
Mutant ras epitopes as targets for cancer vaccines.
Semin. Oncol. 23: 118-34, 1996. [Journal]
52)  Cole DJ, Wilson MC, Baron PL, O'Brien P, Reed C, Tsang KY, Schlom J.
Phase I study of recombinant CEA vaccinia virus vaccine with post vaccination CEA peptide challenge.
Hum. Gene Ther. 7: 1381-94, 1996. [Journal]
53)  Schlom J, Kantor J, Abrams S, Tsang KY, Panicali D, Hamilton JM.
Strategies for the development of recombinant vaccines for the immunotherapy of breast cancer.
Breast Cancer Res. Treat. 38: 27-39, 1996. [Journal]
54)  Tsang KY, Zaremba S, Nieroda CA, Zhu MZ, Hamilton JM, Schlom J.
Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine.
J. Natl. Cancer Inst. 87: 982-90, 1995. [Journal]
55)  Yamaue H, Kashmiri SV, De Filippi R, Nieroda C, Yannelli JR, Tsang KY, Schlom J.
Enhanced interleukin-2 production in human tumor-infiltrating lymphocytes engineered by 3'-truncated interleukin-2 gene.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy. 16: 262-74, 1994. [Journal]
56)  Tsang KY, Kashmiri SV, De Filippi R, Qi CF, Calvo B, Shu L, Nieroda CA, Greiner JW, Schlom J.
A human T cell line engineered to secrete chimeric monoclonal antibody.
J. Immunother. 13: 143-52, 1993. [Journal]
57)  Arlen M, Hollinshead AC, Tsang KY.
Identification and characterization of a colon tumor-associated antigen.
Ann. N. Y. Acad. Sci. 690: 374-5, 1993. [Journal]
58)  Arlen M, Tsang KY.
Monoclonal antibodies and their role in modulation of the immune response.
Journal of surgical oncology. 54: 103-8, 1993. [Journal]
59)  Tsang KY, Kashmiri SV, Qi CF, Nieroda C, Calvo B, De Filippi R, Greiner JW, Primus FJ, Schlom J.
Transfer of the IL-6 gene into a human colorectal carcinoma cell line and consequent enhancement of tumor antigen expression.
Immunol. Lett. 36: 179-85, 1993. [Journal]
60)  Tsang KY, Finch MD, Primus FJ, Schlom J.
Human recombinant interleukin-6 enhances antibody-dependent cellular cytotoxicity of human tumor cells mediated by human peripheral blood mononuclear cells.
Cancer Immunol. Immunother. 34: 9-16, 1991. [Journal]
61)  Warren RQ, Tsang KY.
Induction of immunity to a human osteosarcoma-associated antigen in mice using anti-idiotypic antibodies.
Clin. Immunol. Immunopathol. 56: 334-43, 1990. [Journal]
62)  Xu D, Tsang KY.
Nucleotide sequence of a new BALB/c mouse kappa light chain variable region gene.
Nucleic Acids Res. 18: 1912, 1990. [Journal]
63)  Tsang KY, Johnson EA, La Via MF.
Anti-p24 antibody reactivity in the acquired immunodeficiency syndrome (AIDS)-related complex treated with isoprinosine.
Ann. Intern. Med. 109: 595, 1988. [Journal]
64)  Warren RQ, Johnson EA, Donnelly RP, Lavia MF, Tsang KY.
Specificity of anti-lymphocyte antibodies in sera from patients with AIDS-related complex (ARC) and healthy homosexuals.
Clin. Exp. Immunol. 73: 168-73, 1988. [Journal]
65)  Tsang KY, Pan JF, Fudenberg HH.
An animal model for evaluation of antigen-specific dialyzable leukocyte extracts therapy of osteosarcoma.
Clin. Immunol. Immunopathol. 42: 360-9, 1987. [Journal]
66)  Donnelly RP, La Via MF, Tsang KY.
Humoral-mediated suppression of interleukin 2-dependent target cell proliferation in acquired immune deficiency syndrome (AIDS): interference with normal IL-2 receptor expression.
Clin. Exp. Immunol. 68: 488-99, 1987. [Journal]
67)  Lee JC, Truneh A, Smith MF, Tsang KY.
Induction of interleukin 2 receptor (TAC) by tumor necrosis factor in YT cells.
J. Immunol. 139: 1935-8, 1987. [Journal]
68)  Johnson E, Miribel L, Arnaud P, Tsang KY.
Purification of IgM monoclonal antibody from murine ascitic fluid by a two-step column chromatography procedure.
Immunol. Lett. 14: 159-65, 1987. [Journal]
69)  Tsang KY, Boutin B, Pathak SK, Donnelly R, Koopmann WR, Fleck R, Miribel L, Arnaud P.
Effect of isoprinosine on sialylation of interleukin-2.
Immunol. Lett. 12: 195-200, 1986. [Journal]
70)  Donnelly RP, Tsang KY, Galbraith GM, Wallace JI.
Inhibition of interleukin-2-induced T-cell proliferation by sera from patients with the acquired immune deficiency syndrome.
J. Clin. Immunol. 6: 92-101, 1986. [Journal]
71)  Tsang KY, Donnelly RP, Galbraith GM, Fudenberg HH.
Isoprinosine effects on interleukin-1 production in acquired immune deficiency syndrome (AIDS).
Int. J. Immunopharmacol. 8: 437-41, 1986. [Journal]
72)  Donnelly RP, Tsang KY, Bishop LR, Fudenberg HH.
Kinetic analysis of the immunopotentiating effect of the hypoxanthine analogue, NPT-15392, on the interleukin-2 production potential of human lymphocytes.
Int. J. Immunopharmacol. 8: 621-7, 1986. [Journal]
73)  Tsang KY, Warren RQ, Bishop L, Pathak S, Koger B, LaVia MF.
Monoclonal antibodies to human osteosarcoma-associated antigen(s).
J. Natl. Cancer Inst. 77: 1175-80, 1986. [Journal]
74)  Tsang KY, Fudenberg HH.
Transfer factor and other T cell products.
Springer Semin. Immunopathol. 9: 19-32, 1986. [Journal]
75)  Nel AE, Navailles M, Emerson DL, Goldschmidt-Clermont P, Pathak SK, Tsang KY, Galbraith RM.
Altered configuration of Gc on the plasma membrane of transformed and malignant human B lymphocytes.
Clin. Immunol. Immunopathol. 37: 191-202, 1985. [Journal]
76)  Tsang KY, Pan JF, Swanger DL, Fudenberg HH.
In vitro restoration of immune responses in aging humans by isoprinosine.
Int. J. Immunopharmacol. 7: 199-206, 1985. [Journal]
77)  Pathak SK, Tsang KY, Cathcart MK, Arnaud P, Boutin B, Fudenberg HH.
Partial purification and characterization of B cell growth factor constitutively secreted by human T-cell hybridoma.
Immunol. Lett. 10: 339-46, 1985. [Journal]
78)  Tsang KY, Fudenberg HH, Galbraith GM, Donnelly RP, Bishop LR, Koopmann WR.
Partial restoration of impaired interleukin-2 production and Tac antigen (putative interleukin-2 receptor) expression in patients with acquired immune deficiency syndrome by isoprinosine treatment in vitro.
J. Clin. Invest. 75: 1538-44, 1985. [Journal]
79)  Tsang KY, Fudenberg HH, Pan JF.
Transfer of osteosarcoma-specific cell-mediated immunity in hamsters by rabbit dialyzable leukocyte extracts.
Cell. Immunol. 90: 295-302, 1985. [Journal]
80)  Liu JJ, Segre D, Gelberg HB, Fudenberg HH, Tsang KY, Khansari N, Waltenbaugh CR, Segre M.
Effects of long-term treatment of mice with anti-I-J monoclonal antibody and dialyzable leukocyte extract on immune function and lifespan.
Mech. Ageing Dev. 27: 359-72, 1984. [Journal]
81)  Tsang KY, Hynes JB, Fudenberg HH, Pan JF.
Effects of three new folate antagonists on human breast adenocarcinoma cells in vitro and on immune responses in vivo.
Chemotherapy. 30: 61-8, 1984. [Journal]
82)  Fudenberg HH, Whitten HD, Arnaud P, Khansari N, Tsang KY, Hames CG.
Immune diagnosis of a subset of Alzheimer's disease with preliminary implications for immunotherapy.
Biomed. Pharmacother. 38: 290-7, 1984. [Journal]
83)  Tsang KY, Fudenberg HH, Galbraith GM.
In vitro augmentation of interleukin-2 production and lymphocytes with the TAC antigen marker in patients with AIDS.
N. Engl. J. Med. 310: 987, 1984. [Journal]
84)  Tsang KY, Pan JF, Fudenberg HH.
Production of antibody to human osteosarcoma associated antigens by continuous human lymphoblastoid cell lines.
Immunol. Lett. 7: 267-72, 1984. [Journal]
85)  Tsang KY, Fudenberg HH, Pan JF, Gnagy MJ, Bristow CB.
An in vitro study on the effects of isoprinosine on immune responses in cancer patients.
Int. J. Immunopharmacol. 5: 481-90, 1983. [Journal]
86)  Tsang KY, Fudenberg HH, Sun DC, Pai GS, Bishop LR, Sager S.
Cultivation of human osteosarcoma cell lines in serum-free hormone supplemented medium.
In vitro. 19: 515-21, 1983. [Journal]
87)  Tsang KY, Fudenberg HH, Gnagy MJ.
Restoration of immune responses of aging hamsters by treatment with isoprinosine.
J. Clin. Invest. 71: 1750-5, 1983. [Journal]
88)  Tsang KY, Hynes JB, Fudenberg HH.
Effects of 5,8-dideazaisofolic acid (IAHQ) on human tumor cells in culture and on normal and tumor-bearing hamsters.
Chemotherapy. 28: 276-82, 1982. [Journal]
89)  Pandey JP, Shannon BT, Tsang KY, Fudenberg HH, Camblin JG.
Heterozygosity at Gm loci associated with humoral immunity to osteosarcoma.
J. Exp. Med. 155: 1228-32, 1982. [Journal]
90)  Tsang KY, Pai GS, Fudenberg HH.
Characterization of newly established human osteosarcoma cell line, LM-1.
In vitro. 17: 308-14, 1981. [Journal]
91)  Tsang KY, Gnagy MJ, Yamamura Y, Fudenberg HH.
Detection of natural killer cell-mediated cytotoxicity in hamsters, using Raji target cells.
Clin. Immunol. Immunopathol. 21: 332-40, 1981. [Journal]
92)  Tsang KY, Fudenberg HH.
Isoprinosine as an immunopotentiator in an animal model of human osteosarcoma.
Int. J. Immunopharmacol. 3: 383-9, 1981. [Journal]
93)  Tsang KY, Fudenberg HH, Gnagy MJ.
Osteosarcoma patients: isolation of serum antibodies by affinity chromatography.
J. Natl. Cancer Inst. 67: 1183-9, 1981. [Journal]
94)  Singh I, Tsang KY, Blakemore WS.
A model for human osteosarcoma in hamsters.
Clin. Orthop. Relat. Res. 305-10, 1979. [Journal]
95)  Tsang KY, Singh I, Blakemore WS.
Circulating immune complexes in human osteosarcoma.
J. Natl. Cancer Inst. 62: 743-8, 1979. [Journal]
96)  Tsang KY, Singh I, Blakemore WS.
Human bone-specific alkaline phosphatases from an animal model of human osteosarcoma.
Surgical forum. 30: 500-2, 1979. [Journal]
97)  Tsang KY, Singh I, Blakemore WS.
Detection of circulating immune complexes in human osteosarcoma.
Surgical forum. 29: 560-1, 1978. [Journal]
98)  Singh I, Tsang KY, Blakemore WS.
Placenta-like alkaline phosphatases from human osteosarcoma cells.
Cancer Res. 38: 193-8, 1978. [Journal]
99)  Tsang KY, Hann WD.
Activation of Epstein-Barr virus in hybrid cells.
J. Natl. Cancer Inst. 58: 1295-301, 1977. [Journal]
100)  Singh I, Hatheway JM, Tsang KY, Blakemore WS, McAllister RM.
An animal model for human osteosarcoma.
Surgery. 81: 168-75, 1977. [Journal]
101)  Singh I, Tsang KY, Blakemore WS.
Effect of xenogeneic immune RNA on normal human lymphocytes against human osteosarcoma cells in vitro.
J. Natl. Cancer Inst. 58: 505-10, 1977. [Journal]
102)  Tsang KY, Blakemore WS.
Immunologic studies in contacts of osteosarcoma in humans and animals.
Nature. 265: 541-2, 1977. [Journal]
103)  Singh I, Tsang KY, Blakemore WS.
Isolation and partial purification of plasma membrane-associated antigens from human osteosarcoma (TE-85) cells in tissue culture.
Cancer Res. 36: 4130-6, 1976. [Journal]
104)  Singh I, Tsang KY.
An in vitro production of bone specific alkaline phosphatase.
Exp. Cell Res. 95: 347-58, 1975. [Journal]
105)  Singh I, Tsang KY, Ludwig GD.
Alkaline phosphatase and ultrastructural alterations in human osteosarcoma cells in tissue culture.
European surgical research. Europäische chirurgische Forschung. Recherches chirurgicales européennes. 6: 247-63, 1974. [Journal]
106)  Singh I, Tsang KY, Ludwig GD.
Alterations in the mitochondria of human osteosarcoma cells with glucocorticoids.
Cancer Res. 34: 2946-52, 1974. [Journal]
107)  Qi CF, Nieroda C, De Filippi R, Greiner JW, Correale P, Schlom J, Tsang KY.
Macrophage colony-stimulating factor enhancement of antibody-dependent cellular cytotoxicity against human colon carcinoma cells.
Immunol. Lett. 47: 15-24, , ,. [Journal]
108)  Schlom J, Tsang K, inventor; DHHS, assignee.
A human cytolytic T-lymphocyte epitode and its agonist epitope from the non-variable number of tandem repeat sequence of MUC-1.
Patent Pending, Filed in 2003. Application No. 10/582,702. Pending [Patent]
109)  Panicali D, Gritz L, Hodge JW, Mazzaral G, Schlom J, Tsang K, inventor; DHHS, assignee.
Custom vectors for treating and preventing pancreatic cancer.
Patent Pending, Filed in 2005. Application No. 10/579,025. Pending [Patent]
110)  Panicali D, Gritz L, Hodge JW, Mazzara G, Schlom J, Tsang K, inventor; DHHS, assignee.
System for treating and preventing breast cancer.
Patent Pending, Filed in 2005. Application No. 10/579,007. Pending [Patent]
111)  Schlom J, Tsang K, Panicali D, inventor; DHHS, assignee.
Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof.
US Patent: 6,319,496. 2001. [Patent]
112)  Schlom J, Panicali D, Tsang K, inventor; DHHS, assignee.
Peptide agonists of prostate specific antigen and uses thereof.
US Patent: 7,247,615. 2007. [Patent]
113)  Schlom J, Tsang K, Zaremba S, inventor; DHHS, assignee.
Prostate specific antigen oligo-epitope peptide.
US Patent: 6,946,133. 2005. [Patent]

This page was last updated on 11/24/2008.